Correlation Between SFRP1 and Colorectal Cancer and Adenoma

Correlation Between Methylation Site of SFRP1 Gene Promoter and Colorectal Cancer and Adenoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05204433

Enrollment

220

Registered

2022-01-24

Start date

2019-01-05

Completion date

2022-03-30

Last updated

2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Diagnosis of Colorectal Cancer and Adenoma

Brief summary

In summary, our study demonstrated the methylation sites of SFRP1 gene promoter in patients with colorectal cancer and adenoma and found SFRP1\_16\_17\_18 CpG site was good performance as a diagnostic marker of colorectal cancer.

Interventions

OTHERno intervention

no intervention

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* consecutive adult patients undergoing an outpatient endoscopy and histopathologically diagnosed as colorectal cancer or adenoma. Also, healthy individuals were invited to be enrolled.

Exclusion criteria

* Lynch syndrome * Familial adenomatous polyposis * MUTYH associated polyposis * Peutz-Jeghers syndrome * Juvenile polyposis syndrome * Serrated polyposis syndrome

Design outcomes

Primary

Measure	Time frame	Description
effectiveness of methylation markers from stool samples	3 years	assess the effectiveness of methylation markers from stool samples in colon cancer patients, colorectal adenoma patients, compared with normal volunteers

Secondary

Measure	Time frame
assess the capacities of RF model in screening potential clinical biomarkers.	3 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026